⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377412 | 1.00 | — | — | |
| SCHEMBL2844103 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL4650501 | 0.97 | — | — | |
| SCHEMBL1352284 | 0.92 | — | — | |
| SCHEMBL56375 | 0.92 | — | — | |
| SCHEMBL56946 | 0.92 | — | — | |
| SCHEMBL24760387 | 0.89 | GAA (0.33) | — | |
| Methane SCHEMBL7933332 | 0.89 | GAA (0.33) | — | |
| Hydrochloric Acid SCHEMBL4599773 | 0.89 | GAA (0.33) | — | |
| SCHEMBL31438370 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | claimed |
| US-7582782-B2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2009-09-01 | — | — | US | claimed |
| WO-2021259077-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-12-30 | — | — | WO | disclosed |
| WO-2020061103-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-7851642-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20090253701-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253703-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-7595327-B2 | Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-7582782-B2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2009-09-01 | — | — | US | disclosed |
| US-20070135498-A1 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1689702-A1 | ORGANIC COMPOUNDS | NOVARTIS-PHARMA GMBH (AT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051895-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |